Drag Pharma

Hemodrag® Dogs

Hemostatic and Angioprotective

Indicated for the prevention and treatment of haemorrhages in veterinary surgery, reproductive and obstetric pathologies, accidental traumatology and localised haemorrhages in various organs. It has a hemostatic and angioprotective effect on dermal processes such as petechiae, hematomas and wounds.
Effective for all haemorrhagic processes regardless of their etiology (with the exception of haemorrhages caused by coumarin agents), because it acts on primary haemostasis. In dogs it can be used in tail docking, castration and in puerperal hemorrhages.

Data Sheet

Solution for injection.

Hemostatic and angioprotective.

Each 1 mL contains:
Ethamsilate……………………. 125 mg
Excipients c.s.p……………. 1 mL

Hemodrag® is indicated for the prevention and treatment of haemorrhages in veterinary surgery, reproductive and obstetric pathologies, accidental traumatology and localised haemorrhages in various organs. It has a hemostatic and angioprotective effect on dermal processes such as petechiae, hematomas and wounds.
Hemodrag® is effective for all hemorrhagic processes regardless of their etiology (with the exception of haemorrhages caused by coumarin agents), because it acts on primary haemostasis. It can be used in castrations, tail docking and in puerperal hemorrhages in female dogs.

Dogs.

  • Dose of the active ingredient: 5 to 12.5 mg/kg body weight, in a single dose.
  • Product dose: 0.4 to 1 mL/10 kg body weight, in a single dose.

Slow intravenous or deep intramuscular.

  • Do not administer in cases of acute porphyriasis, as it has been shown to be porphyrogenic in animals.
  • Do not use in animals with known hypersensitivity to the active substance.
  • Keep out of reach of children and pets.
  • This product is indicated for the treatment of individual animals. Do not treat the entire mass of animals.
  • Animals should not be slaughtered for human consumption during and/or immediately after treatment.
  • The product is oxidized in the presence of oxygen, so the remaining volume should be discarded after administration.
  • In the case of intramuscular administration, if the required dose is greater than 20 mL, it is suggested to divide it into two or more application sites.

Do not use concomitantly with other pharmacological products.

They have not been described.

Studies on the tolerance of ethamsylate indicate that it is well tolerated even at much higher than recommended doses.

  • Administer with caution. Wash your hands after applying the product.
  • People with known hypersensitivity to ethamsylate should avoid contact with the drug.
  • Accidental self-injection can lead to altered blood pressure. In case of occurrence, consult a doctor immediately and show the product label.

Store at room temperature, between 15 and 30°C, in a dry place away from light.
Once opened, use within 1 week. Discard the unused product after that period of time.

Dispose of unused product residues in their original packaging. Do not dispose of the empty container or with product residues in rivers, lakes or natural water streams. Dispose of waste of this product with caution along with household waste.

Sale by prescription to the Veterinary Doctor.

VETERINARY USE

Chile: Reg. SAG N° 1967
Peru: Reg. SENASA F.F3.01.I.0009
Costa Rica: Reg. No. MV-7150

4 ampoule bottles of 5 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.

*Important:

You have accessed information referring to pharmaceutical products authorized for sale under a medical prescription. In accordance with Chilean legislation, the promotion and advertising of these products is restricted to professionals who prescribe and dispense them. The information contained on this page is specialized technical and scientific information.